查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715777

按产品类型、更年期阶段、给药途径和分销管道分類的更年期市场 - 2025-2030 年全球预测

Menopause Market by Product Type, Stage of Menopause, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年更年期市场价值将达到 199.7 亿美元，2025 年将成长至 213.9 亿美元，复合年增长率为 7.32%，到 2030 年将达到 305.2 亿美元。

主要市场统计数据
基准年2024年 199.7亿美元
预计年份：2025年 213.9亿美元
预测年份 2030 305.2亿美元
复合年增长率（%） 7.32%

近年来，更年期市场的复杂性显着增加。本综合概述探讨了持续塑造这一独特成长领域的各个因素。在当今的医疗保健领域，由于社会观念和消费者需求的变化，更年期和相关症状的管理越来越受到关注。深入了解荷尔蒙疗法和非荷尔蒙疗法以及患者的特定偏好，不仅可以洞察治疗的可能性，而且还强调了创新和差异化服务的重要性。

这次深入讨论探讨了治疗通讯协定的进步和不断变化的患者人口结构如何促进市场转型。广泛的宣传宣传活动、创新的药物配方以及数位手段的整合共同推动了该行业进入新的领域。本评论将成为相关人员了解更年期照护进展和未来方向的重要参考。在以下章节中，我们将有系统地分解市场细分，回顾关键的区域动态，并专注于推动这些变化的关键公司。在整个分析过程中，必须牢记，正在进行的研究和不断发展的治疗策略对于解决当前的治疗差距和释放未来的成长仍然至关重要。

我们的见解以严格的数据分析和市场评估为后盾，确保我们反映医疗保健产业面临的最新趋势和挑战。临床研究的进步与患者体验之间的动态交互作用重新定义了治疗方案的设计和提供方式。在此过程中，它还仔细审查了市场对关键需求的反应，使该书成为医疗专业人士和行业远见者的重要资讯来源。

改变更年期市场

近年来，人们对更年期的认识和管理方式发生了巨大变化。技术创新、不断变化的监管环境以及对以患者为中心的护理的更加重视共同重新定义了治疗格局。新的研究和临床测试使得各种治疗方法的接受度和使用率有所提高。随着新治疗方法不断获得信誉，现有的市场规范也不断重组。

利用数位技术监测患者健康状况并实现远距离诊断正在彻底改变专业医疗服务的获取方式，从而改变社区推广和服务提供方式。此外，从传统的荷尔蒙疗法到先进的非荷尔蒙替代疗法，不断发展的药物配方正在为患者管理带来更大的灵活性。产品开发和监管核准步伐的加快证明了这一点，这增加了市场活力。

此外，政府政策和市场相关人员正在共同努力提高透明度和可及性。减少健康差距和促进预防保健的动力正在引发创新的定价模式和新的分销策略。最终，这种转变促使许多产业相关人员重新调整其策略重点，大力投资技术和临床研究，以期为治疗更年期症状提供更先进的方法。这种动态调整不仅重塑了患者的期望，而且为该领域的长期持续成长奠定了基础。

关键细分洞察

详细了解市场区隔可以揭示更年期治疗的复杂状况。市场大致根据产品类型、闭经阶段、给药途径和分销管道进行细分。根据产品类型，我们区分荷尔蒙补充疗法（HRT）和非荷尔蒙疗法。 HRT 部分进一步细分为雌激素-黄体素联合治疗、雌激素疗法和黄体素疗法。非荷尔蒙治疗选择包括抗忧郁症、植物补充剂、Gabapentin和Pregabalin。在抗忧郁症类别中，某些化合物如西酞普兰、escitalopram和Fluoxetine之间有进一步的区分。

此外，根据更年期阶段（更年期、围闭经和停经后疾病）对市场进行细分，可以揭示出一种细緻的患者照护方法。每个阶段都有其自身的生理挑战和治疗要求，需要量身定制的治疗策略。

同样重要的部分是由给药途径定义的，市场分为肠内、肠外和局部方法。这种分类强调了不同的疗效、患者的舒适度以及与治疗相关的偏好。

最后，分销管道在确保产品供应和及时交付方面发挥着至关重要的作用。市场透过医院药局、网路药局和零售药局等管道进行分析。创新的线上平台包括从企业网站到专用电子商务入口网站等管道，从而提高了便利性和患者覆盖率。综合起来，这些细分洞察让相关人员清楚地了解消费行为、技术进步和不断变化的监管环境，所有这些都已成为策略决策和市场扩张的重要组成部分。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 对更年期症状的认识和诊断不断提高，推动了对专业护理的需求
      • 人口老化和女性预期寿命的延长正在扩大更年期产品的市场。
      • 更年期症状出现较早且盛行率增加，影响范围更广
    • 限制因素
      • 更年期解决方案的研发和临床测试高成本
    • 机会
      • 开发全面的远距远端医疗解决方案，提供个人化的健康评估和远距指导
      • 革命性的穿戴式健康监测设备透过即时分析追踪荷尔蒙变化和症状
    • 任务
      • 更年期护理行业的监管和合规障碍
  • 市场区隔分析
    • 产品类型：消费者对天然健康替代品的兴趣日益浓厚，导致非荷尔蒙疗法的采用率不断上升
    • 分销管道：消费者越来越偏好能够提供临床监督并确保处方笺准确性的医院药房
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 更年期市场（依产品类型）

  • 介绍
  • 荷尔蒙补充疗法（HRT）
    • 雌激素-黄体素联合治疗
    • 雌激素治疗
    • 黄体素治疗
  • 非荷尔蒙疗法
    • 抗忧郁症
      • 西酞普兰
      • escitalopram
      • Fluoxetine
    • 植物补充剂
    • Gabapentin
    • Pregabalin

第七章 更年期障碍市场（依更年期障碍阶段）

  • 介绍
  • 停经
  • 停经
  • 停经后

第八章 更年期障碍市场（依给药途径）

  • 介绍
  • 肠内
  • 肠外
  • 局部的

第九章 更年期障碍市场（依通路）

  • 介绍
  • 医院药房
  • 网路药局
    • 公司网站
    • 电商平台
  • 零售药局

10. 美洲更年期市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太更年期市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲更年期市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Abbvie Inc.
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Ltd.
  • Eli Lilly and Company
  • Ferring International Center SA
  • Fervent Pharmaceuticals, LLC
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Ipsen Group
  • Merck & Co.Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.
  • Viatris Inc.
Product Code: MRR-B973EDD5E621

The Menopause Market was valued at USD 19.97 billion in 2024 and is projected to grow to USD 21.39 billion in 2025, with a CAGR of 7.32%, reaching USD 30.52 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 19.97 billion
Estimated Year [2025] USD 21.39 billion
Forecast Year [2030] USD 30.52 billion
CAGR (%) 7.32%

The complexities of the menopause market have evolved significantly over recent years. This comprehensive overview explores the diverse factors that continue to shape a unique and growing sector. In today's healthcare landscape, the management of menopause and related symptoms has garnered increased attention, driven by shifting societal perceptions and consumer needs. A deeper understanding of hormonal and non-hormonal therapies, along with patient-specific preferences, not only offers insights into the therapeutic potential but also underlines the importance of innovation and differentiated service.

In this detailed narrative, we explore how advances in treatment protocols and evolving patient demographics have contributed to the transformative nature of the market. Broad awareness campaigns, innovative drug formulations, and the integration of digital avenues have collectively pushed the industry into new territories. This discussion serves as a fundamental reference for stakeholders looking to grasp the progress made as well as the future direction of menopause treatments. In subsequent sections, we will systematically break down the market segmentation, review key regional dynamics, and highlight the pivotal companies driving these changes. Throughout the analysis, it is essential to note that continual research and evolving treatment strategies remain central to both addressing current gaps in care and unlocking future growth.

Our discussion is backed by rigorous data analysis and market evaluation, ensuring that the insights reflect the latest trends and challenges faced by the healthcare industry. The dynamic interplay between clinical research advancements and patient experience has redefined how therapeutic solutions are designed and delivered. In doing so, the market's response to critical needs is also scrutinized, making this narrative a vital resource for healthcare professionals and industry visionaries alike.

Transformative Shifts in Menopause Market Landscape

Recent years have witnessed seismic shifts in the way menopause is perceived and managed. A combination of technological innovation, regulatory changes, and a more robust focus on patient-centric care has redefined the treatment landscape. Emerging research studies and clinical trials have bolstered the acceptance and use of varying therapeutic approaches. As novel therapies continue to gain trust, existing market norms are continually restructured.

The integration of digital technologies in monitoring patient health and enabling remote diagnosis has revolutionized access to specialized care, thereby transforming regional outreach and service delivery. Additionally, the evolution of pharmaceutical formulations - from traditional hormonal therapies to advanced non-hormonal alternatives - has driven increased adaptability in patient management. This is evidenced by an accelerating pace of product development and regulatory approvals that have nurtured a heightened level of market dynamism.

Furthermore, government policies and market stakeholders have collectively contributed to enhancing transparency and accessibility. The drive to mitigate health disparities and promote preventive care has led to innovative pricing models and new distribution strategies. Ultimately, these shifts have precipitated a realignment in strategic focus for many industry players, who are now investing heavily in technologies and clinical research that promise a more refined approach to managing menopause. This dynamic realignment has not only restructured patient expectations but also set the stage for sustained long-term growth in the sector.

Key Segmentation Insights

An in-depth examination of market segmentation provides clarity into the complexities of the menopause treatment landscape. The market is broadly classified based on product type, stage of menopause, route of administration, and distribution channel. In the realm of product type, the analysis differentiates between Hormone Replacement Therapy (HRT) and non-hormonal treatments. The HRT segment is elaborated further into combined estrogen-progesterone therapies, estrogen therapies, and progesterone therapies. Meanwhile, non-hormonal treatments comprise an array of options including antidepressants, botanical supplements, gabapentin, and pregabalin. Within the antidepressants category, further distinctions are made among specific compounds such as citalopram, escitalopram, and fluoxetine.

Additionally, the market segmentation by stage of menopause reveals a nuanced approach to patient care, with distinct considerations for individuals undergoing menopause, perimenopause, and postmenopause. Each stage is characterized by unique physiological challenges and treatment requisites, necessitating tailored therapeutic strategies.

An equally important segment is defined by the route of administration, where the market is segmented into enteral, parenteral, and topical methods. This classification highlights varying efficacy, patient comfort, and preferences linked to the delivery of therapeutic agents.

Finally, distribution channels play a critical role in ensuring accessibility and timely delivery of products. The market is profiled through channels such as hospital pharmacies, online pharmacies, and retail pharmacies. Innovative online platforms include channels ranging from company websites to dedicated eCommerce portals, facilitating greater convenience and broadening patient reach. Collectively, these segmentation insights offer stakeholders a clear understanding of consumer behavior, technological progression, and the evolving regulatory landscape, all of which serve as essential building blocks for strategic decision-making and market expansion.

Based on Product Type, market is studied across Hormone Replacement Therapy (HRT) and Non-Hormonal Treatments. The Hormone Replacement Therapy (HRT) is further studied across Combined Estrogen-Progesterone Therapy, Estrogen Therapy, and Progesterone Therapy. The Non-Hormonal Treatments is further studied across Antidepressants, Botanical Supplements, Gabapentin, and Pregabalin. The Antidepressants is further studied across Citalopram, Escitalopram, and Fluoxetine.

Based on Stage of Menopause, market is studied across Menopause, Perimenopause, and Postmenopause.

Based on Route of Administration, market is studied across Enteral, Parenteral, and Topical.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is further studied across Company Websites and eCommerce Platforms.

Key Regional Insights

The evolving landscape of menopause treatments is distinctly shaped by regional dynamics, which offer valuable perspectives on market evolution across different territories. In the Americas, extensive research and robust healthcare infrastructure have fostered significant innovation in therapeutic solutions, leading to widespread adoption of both hormonal and non-hormonal treatment modalities. The presence of well-established clinical research centers and a strong regulatory framework have further stimulated market growth.

Across Europe, the Middle East, and Africa, the market is characterized by a blend of traditional treatment approaches and modern pharmaceutical innovations. This region has experienced steady expansion, bolstered by community-driven healthcare initiatives and progressive government policies that emphasize preventive care. Collaborative partnerships between academic institutions, industry players, and healthcare providers have also cultivated a rich environment for continuous improvement in patient care.

In the Asia-Pacific region, rapid urbanization coupled with rising income levels has led to an increased demand for advanced healthcare services, particularly in specialized fields such as menopause management. Here, an evolving consumer base is embracing both conventional and novel treatment options, driven by greater health awareness and improved access to state-of-the-art medical facilities. Together, these regional insights underscore the diverse and multifaceted nature of the market, helping geostrategic planners to better align technologies, regulatory considerations, and distribution strategies tailored to local specifics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

Several industry leaders continue to shape and influence the menopause treatment market with their extensive portfolios and robust R&D pipelines. Among these, Abbott Laboratories and Abbvie Inc. have consistently demonstrated innovative approaches in developing both traditional and novel therapeutic interventions. Prominent players such as Amgen Inc., Apotex Inc., and Astellas Pharma Inc. contribute significantly to driving clinical advancements and broadening treatment options available to patients. As companies like AstraZeneca PLC, Bayer AG, and Cipla Ltd. invest in targeted research initiatives, they pave the way for enhanced therapeutic efficacy and patient satisfaction.

Industry giants including Eli Lilly and Company, Ferring International Center S.A., and Fervent Pharmaceuticals, LLC are also at the forefront of integrating advanced technologies in drug development and market penetration strategies. Alongside them, companies such as Gedeon Richter PLC, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Ltd. continue to refine treatment methodologies to meet evolving patient needs. Additional noteworthy contributors include Ipsen Group, Merck & Co.Inc., Mithra Pharmaceuticals S.A., Novartis AG, Novo Nordisk A/S, and Organon & Co, who have already begun to influence market trajectories significantly. Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc., and Viatris Inc. further exemplify the competitive nature of the market, with each entity offering unique insights and solutions that help drive the evolution of menopause management. Together, these companies are fostering an environment where innovation, efficiency, and competitive pricing remain central to meeting the ever-growing demand for advanced healthcare solutions.

The report delves into recent significant developments in the Menopause Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abbvie Inc., Amgen Inc., Apotex Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Eli Lilly and Company, Ferring International Center S.A., Fervent Pharmaceuticals, LLC, Gedeon Richter PLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Ipsen Group, Merck & Co.Inc., Mithra Pharmaceuticals S.A., Novartis AG, Novo Nordisk A/S, Organon & Co, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc., and Viatris Inc.. Actionable Recommendations for Industry Leaders

Industry stakeholders are encouraged to adopt strategies that align closely with patient needs and evolving market trends. One of the most critical recommendations is to invest in innovative research and development programs that bridge the gap between traditional therapeutic models and emerging non-hormonal solutions. Embracing digital transformation is also essential to enhance patient engagement, improve service delivery, and increase market responsiveness.

Leaders should consider forging strategic partnerships across academic institutions, technology providers, and regulatory bodies to promote a more integrated approach to patient care. Such collaborative initiatives can yield comprehensive insights into patient behaviors and enable more efficient integration of sophisticated treatment technologies. In parallel, companies should emphasize the customization of solutions based on detailed segmentation analyses that consider product types, stages of menopause, routes of administration, and distribution channels.

Optimizing distribution channels is another key area where industry players can drive value. By leveraging advanced logistics networks and broadening digital sales platforms, companies can significantly enhance market penetration and accessibility. Firms are advised to focus on both established and emerging markets to harness growth opportunities available across various geographies.

Finally, maintaining a strong commitment to regulatory compliance and clinical excellence will be pivotal. Continuous monitoring of market trends and patient satisfaction metrics can provide a roadmap for refining both product offerings and distribution strategies over time. These recommended practices are designed to create a resilient market environment, ensuring that innovative solutions remain at the forefront of menopause management while simultaneously addressing the unique needs of a diverse patient population.

Conclusion & Strategic Outlook

The menopause treatment landscape is undergoing a remarkable evolution, driven by the confluence of technological advancements, evolving therapeutic paradigms, and shifting patient expectations. The detailed analysis presented here establishes a robust foundation for understanding the key drivers, trends, and strategic imperatives crucial to navigating this complex market.

A confluence of factors-ranging from advanced drug formulations and innovative administration routes to evolving distribution channels-has together sculpted a dynamic and responsive market environment. Clear differentiation in product types and nuanced segmentation based on life stages underscores the importance of personalized treatment solutions that cater to diverse patient needs.

Moreover, the regional insights reveal varied market dynamics that provide strategic direction to global and local stakeholders alike. The efforts of industry-leading companies further exemplify the commitment towards leveraging cutting-edge research and technological solutions. These collective trends underscore that the future of menopause management lies in a synergistic approach that harmonizes research excellence, technology adoption, and patient-centric care.

In conclusion, the sector is poised for sustained growth if industry leaders remain agile in their strategic execution, continuously adapting to emerging trends and regulatory changes. A thoughtful and data-driven approach will be essential to fully capitalize on the exciting opportunities presented by this evolving market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness and diagnosis of menopause symptoms driving demand for specialized care
      • 5.1.1.2. Rising aging population and extended female lifespan contributing to a larger market for menopausal products
      • 5.1.1.3. Growing prevalence of early onset menopause and perimenopause conditions affecting a wider demographic
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and clinical trials in developing menopause solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of comprehensive telemedicine solutions to provide personalized menopause health assessments and remote guidance
      • 5.1.3.2. Innovative wearable health monitoring devices that track hormonal changes and menopause symptoms with real-time analysis
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and compliance hurdles within the menopause healthcare industry
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Growing adoption of non-hormonal treatments due to increasing consumer interest in natural wellness alternatives
    • 5.2.2. Distribution Channel: Rising consumer preference for hospital pharmacies ensuring clinical oversight and prescription accuracy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Menopause Market, by Product Type

  • 6.1. Introduction
  • 6.2. Hormone Replacement Therapy (HRT)
    • 6.2.1. Combined Estrogen-Progesterone Therapy
    • 6.2.2. Estrogen Therapy
    • 6.2.3. Progesterone Therapy
  • 6.3. Non-Hormonal Treatments
    • 6.3.1. Antidepressants
      • 6.3.1.1. Citalopram
      • 6.3.1.2. Escitalopram
      • 6.3.1.3. Fluoxetine
    • 6.3.2. Botanical Supplements
    • 6.3.3. Gabapentin
    • 6.3.4. Pregabalin

7. Menopause Market, by Stage of Menopause

  • 7.1. Introduction
  • 7.2. Menopause
  • 7.3. Perimenopause
  • 7.4. Postmenopause

8. Menopause Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Enteral
  • 8.3. Parenteral
  • 8.4. Topical

9. Menopause Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
    • 9.3.1. Company Websites
    • 9.3.2. eCommerce Platforms
  • 9.4. Retail Pharmacies

10. Americas Menopause Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Menopause Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Menopause Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coral secures CAD 4.1 million seed funding led by Brightspark to launch an integrated digital platform
    • 13.3.2. Carrot Fertility's virtual menopause and midlife clinic harnesses telemedicine for hormone therapy
    • 13.3.3. Emcure Pharmaceuticals unveils Arth lineup to support women's health during menopause with affordable solutions
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abbvie Inc.
  • 3. Amgen Inc.
  • 4. Apotex Inc.
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. Cipla Ltd.
  • 9. Eli Lilly and Company
  • 10. Ferring International Center S.A.
  • 11. Fervent Pharmaceuticals, LLC
  • 12. Gedeon Richter PLC
  • 13. GlaxoSmithKline PLC
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. Ipsen Group
  • 16. Merck & Co.Inc.
  • 17. Mithra Pharmaceuticals S.A.
  • 18. Novartis AG
  • 19. Novo Nordisk A/S
  • 20. Organon & Co
  • 21. Pfizer Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. TherapeuticsMD Inc.
  • 25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. MENOPAUSE MARKET MULTI-CURRENCY
  • FIGURE 2. MENOPAUSE MARKET MULTI-LANGUAGE
  • FIGURE 3. MENOPAUSE MARKET RESEARCH PROCESS
  • FIGURE 4. MENOPAUSE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MENOPAUSE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MENOPAUSE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES MENOPAUSE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. MENOPAUSE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. MENOPAUSE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MENOPAUSE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MENOPAUSE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MENOPAUSE MARKET DYNAMICS
  • TABLE 7. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MENOPAUSE MARKET SIZE, BY COMBINED ESTROGEN-PROGESTERONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MENOPAUSE MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MENOPAUSE MARKET SIZE, BY PROGESTERONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MENOPAUSE MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MENOPAUSE MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MENOPAUSE MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MENOPAUSE MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MENOPAUSE MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MENOPAUSE MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MENOPAUSE MARKET SIZE, BY MENOPAUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MENOPAUSE MARKET SIZE, BY PERIMENOPAUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MENOPAUSE MARKET SIZE, BY POSTMENOPAUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MENOPAUSE MARKET SIZE, BY ENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MENOPAUSE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MENOPAUSE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MENOPAUSE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MENOPAUSE MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MENOPAUSE MARKET SIZE, BY ECOMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MENOPAUSE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 65. CANADA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES MENOPAUSE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 107. CHINA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 115. INDIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 252. ITALY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 284. POLAND MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 292. QATAR MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 330. SWEDEN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. SWEDEN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 338. SWITZERLAND MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 346. TURKEY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. TURKEY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 358. UNIT